SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


        Date of report (Date of earliest event reported): March 22, 2006


                         AMERICAN BIO MEDICA CORPORATION
                -------------- --------------------------------
             (Exact Name of Registrant as Specified in its Charter)

          New York                     0-28666                  14-1702188
-----------------------------  -----------------------    ----------------------
(State or Other Jurisdiction   (Commission File Number)      (IRS Employer
     of Incorporation)                                    Identification Number)



                  122 Smith Road, Kinderhook, NY                      12106
                  ---------------------------------------------------------
               (Address of Principal Executive Offices)          (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243

                                 Not applicable
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13c-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

                                       2

<PAGE>


ITEM 3.01. NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD; TRANSFER OF LISTING.

            On March 22,  2006,  the  Company  received a notice from the Nasdaq
Stock Market  informing  the Company that for the last 30  consecutive  business
days,  the bid price of the Company's  common stock has closed below the minimum
$1.00 per share  requirement  for continued  inclusion  under  Marketplace  Rule
4310(c)(4).

            The letter stated that under  Marketplace  Rule  4310(c)(8)(d),  the
Company will be provided with 180 calendar days, or until September 18, 2006, to
regain  compliance  with  Marketplace  Rule  4310(c)(4).  To regain  compliance,
anytime before  September 18, 2006, the bid price of the Company's  common stock
must close at $1.00 per share or more for a minimum of 10  consecutive  business
days.


<PAGE>

      SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                          AMERICAN BIO MEDICA CORPORATION
                                          (Registrant)


Dated: March 24, 2006                     By:      /s/ Keith E. Palmer
                                             -----------------------------------
                                                   Keith E. Palmer
                                                   Chief Financial Officer

                                       3
{"company-data": {"conformed-name": "AMERICAN BIO MEDICA CORP", "cik": "0000896747", "assigned-sic": "2834", "irs-number": "141702188", "state-of-incorporation": "NY", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28666", "film-number": "06707002"}, "business-address": {"street1": "122 SMITH ROAD", "city": "KINDERHOOK", "state": "NY", "zip": "12106", "phone": "5187588158"}, "mail-address": {"street1": "122 SMITH ROAD", "city": "KINDERHOOK", "state": "NY", "zip": "12106"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of report (Date of earliest event reported): March 22, 2006

                         AMERICAN BIO MEDICA CORPORATION
                -------------- --------------------------------
             (Exact Name of Registrant as Specified in its Charter)

          New York                     0-28666                  14-1702188
-----------------------------  -----------------------    ----------------------
(State or Other Jurisdiction   (Commission File Number)      (IRS Employer
     of Incorporation)                                    Identification Number)

                  122 Smith Road, Kinderhook, NY                      12106
                  ---------------------------------------------------------
               (Address of Principal Executive Offices)          (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243

                                 Not applicable
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13c-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

                                       2
ITEM 3.01. NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD; TRANSFER OF LISTING.

            On March 22,  2006,  the  Company  received a notice from the Nasdaq
Stock Market  informing  the Company that for the last 30  consecutive  business
days,  the bid price of the Company's  common stock has closed below the minimum
$1.00 per share  requirement  for continued  inclusion  under  Marketplace  Rule
4310(c)(4).

            The letter stated that under  Marketplace  Rule  4310(c)(8)(d),  the
Company will be provided with 180 calendar days, or until September 18, 2006, to
regain  compliance  with  Marketplace  Rule  4310(c)(4).  To regain  compliance,
anytime before  September 18, 2006, the bid price of the Company's  common stock
must close at $1.00 per share or more for a minimum of 10  consecutive  business
days.
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                          AMERICAN BIO MEDICA CORPORATION
                                          (Registrant)

Dated: March 24, 2006                     By:      /s/ Keith E. Palmer
                                             -----------------------------------
                                                   Keith E. Palmer
                                                   Chief Financial Officer

                                       3